Screener
Madrigal Pharmaceuticals, Inc. MDGL Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Madrigal Pharmaceuticals, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s debt-to-equity?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported debt-to-equity of 0.7× in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s debt-to-equity changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s debt-to-equity increased by 270.4% year-over-year, from 0.2× to 0.7×.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s debt-to-equity?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s debt-to-equity has grown at a 180.9% compound annual growth rate (CAGR), from 0× to 0.6×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude